Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix

Area of Science:

• Biochemistry and Molecular Biology
• Cancer Research and Therapeutics
• Immunology

Background:

• Tumor-associated macrophages (TAMs) promote cancer progression and immune suppression.
• TAM receptors, including MerTK, are promising therapeutic targets.
• Selective MerTK inhibition is crucial to avoid neurotoxicity from Tyro3 inhibition.

Purpose of the Study:

• To design novel, MerTK-selective inhibitors.
• To explore modulating the αC helix conformational dynamics for kinase selectivity.
• To identify a potent and selective MerTK inhibitor for cancer therapy.

Main Methods:

• Integration of structural biology, medicinal chemistry, and protein stabilization assays.
• Molecular docking studies to identify potential inhibitor compounds.
• Pharmacokinetic evaluations and in vivo studies to assess compound efficacy and safety.

Main Results:

• Identification of compound 11, demonstrating potent and selective MerTK inhibition.
• Compound 11 exhibits promising pharmacokinetic properties and in vivo efficacy.
• The study validates a strategy for designing selective kinase inhibitors targeting αC helix conformation.

Conclusions:

• Compound 11 is a promising candidate for further development as a MerTK-targeted cancer therapeutic.
• Modulating αC helix conformation is an effective strategy for achieving MerTK selectivity.
• This work advances understanding of MerTK inhibition and offers a novel approach for selective kinase inhibitor design.